In highly resistant spherical cancer cells, which results from enhanced self-renewal via cyclin D1 and cyclin D1-dependent activation of Smad2/3 and Smad4 (Figures 1, 2, 3), inducing differentiation with Smad inhibitor is a critical tactic for turning resistant CSCs into therapy-sensitive cells. Here, SMAD2 is linked to cancer.